



# EMA – Regulatory Science to 2025

**Session 1: Responding to the needs of the 21<sup>st</sup> century patient. Addressing challenges and opportunities across the European Regulatory Framework**

**Olga Solomon**

# Horizon Europe

is the Commission proposal for a research and innovation funding programme for seven years (2021-2027)



**to strengthen the EU's scientific and technological bases**



**to boost Europe's innovation capacity, competitiveness and jobs**



**to deliver on citizens' priorities and sustain our socio-economic model and values**

# Real world data in health care

Multiple sources of data:

- Clinical databases (prescriptions, EHR, registries)
- Clinical trials
- Imaging data
- 'Omic data'
- Published literature
- Regulatory pharmacovigilance data
- Social media/mHealth data



# Commission Communication of 25 April

## 3 Priority areas on digitising Health and Care



# EU Legislation on Clinical Trials


## *Regulation EU No 536/2014*



*"It's a big misconception. Everyone thinks hell is all fire. Actually, it's all paperwork."*

- Simplified and harmonized administrative provisions
- Closer coordination between MS for international CTs
- Increased transparency

# Evaluation of the paediatric and of the orphan regulations



# Evaluation

- Identification of the problems;
  - Strengths and weaknesses of paediatric and orphan legislations alone and combined;
  - How incentives have been used;
- Finalisation by the end of 2019;
- Base for the next Commission to decide future policy choices.



# From Directives to Regulations

*Directive 90/385/EEC on active implantable medical devices*

*Directive 93/42/EEC on medical devices*

→ **Regulation on MD (2017/745)**

*Directive 98/79/EC on in vitro diagnostic medical devices*

→ **Regulation on IVD (2017/746)**

*Necessity to harmonise the legislation in Member States*

*and to adapt to health scandals:*

*PIP implants; metal on metal hip implants...*



# Health Technology Assessment (HTA)

**Proposal for a Regulation**  
31 January 2018

## WHAT'S NEW?

**Common European assessment methods**

**Shared data and expertise**

**Common procedures across the EU**



## WHAT ARE THE BENEFITS

**Higher level of human health protection**

**Faster market access for innovative products**

**More transparency for patients and producers**

**No more duplication of work for health authorities and industry**



## NEW MEDICINES



**EU ASSESSMENT**  
(jointly done by the Member States)

**NATIONAL ASSESSMENT**

**CLINICAL ASSESSMENT**  
(benefits compared to existing treatments)

**NON-CLINICAL ASSESSMENT**  
(economic, social and ethical aspects)

*National decisions on pricing and reimbursement*


## NEW MEDICAL DEVICES

High-risk devices with high impact on patients, public health and EU health systems

**CLINICAL ASSESSMENT**  
(benefits compared to existing treatments)

**NON-CLINICAL ASSESSMENT**  
(economic, social and ethical aspects)

# Implementation and Looking to the future





**Thank you for your attention !**